Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 18/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 18/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 15/20 | 0.45 |
| ▸ | CASP1 | P29466 | 14/20 | 0.45 |
| ▸ | CASP7 | P55210 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.45 |
| ▸ | HPGD | P15428 | 9/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 8/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849377 | 0.88 | ALDH1A1 (0.42) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1849473 | 0.83 | ALDH1A1 (0.48) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1844713 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1844326 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL8810726 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL9686640 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL9686720 | 0.77 | HTT (0.61) | ALDH1A1HSD17B10CASP1HPGDTSHR | |
| SCHEMBL1921498 | 0.76 | ALDH1A1 (0.42) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL9684477 | 0.75 | HSD17B10 (0.49) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| Maleic Acid SCHEMBL2874748 | 0.75 | HSD17B10 (0.41) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324023-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2009070164-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA (US) | 2009-06-04 | — | — | WO | claimed |
| US-20080124306-A1 | Vigor Enhancement Via Administration of Pyrimidine Derivatives | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2008-05-29 | — | — | US | claimed |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | Progenicyte Therapeutics, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20200246334-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20190167674-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20180092913-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2018-04-05 | — | — | US | disclosed |
| EP-2326330-B1 | COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS | UNIV CENTRAL FLORIDA RES FOUND (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8791128-B2 | Compositions for treating or delaying the onset of hair loss | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110190320-A1 | Compositions for Treating or Delaying the Onset of Hair Loss | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2006133876-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSM IP ASSETS B.V. (NL) | 2006-12-21 | — | — | WO | disclosed |
| US-5976523-A | PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES | MITSUI PHARMACEUTICALS, INC. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0743066-A2 | Wound-healing agent | MITSUI PHARMACEUTICALS, INC. (JP) | 1996-11-20 | — | — | EP | disclosed |
| EP-0188094-B1 | QUINAZOLINE DERIVATIVES AND ANTIHYPERTENSIVE PREPARATIONS CONTAINING SAME AS EFFECTIVE COMPONENTS | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| EP-0192783-B1 | 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4742165-A | HERBICIDES | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| US-4734418-A | Quinazoline compounds and antihypertensives | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0192783-A1 | 2-PIPERAZINOPYRIMIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-09-03 | — | — | EP | disclosed |
| EP-0188094-A2 | Quinazoline derivatives and antihypertensive preparations containing same as effective components | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124306-A1 | Vigor Enhancement Via Administration of Pyrimidine Derivatives | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
| US-20190167674-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | PSEN1, PSEN2, NES | ALDH1A1 4397/4885CYP1A2 4466/4885HSD17B10 873/4885 |
| US-20110190320-A1 | Compositions for Treating or Delaying the Onset of Hair Loss | SHBG, CYP19A1, TYMP | ALDH1A1 1649/4885CYP1A2 1268/4885HSD17B10 518/4885 |
| US-20180092913-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | NES, PSEN1, PSEN2 | ALDH1A1 2409/4885CYP1A2 4390/4885HSD17B10 4301/4885 |
| US-20200246334-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.